MedPath

Effects of the COVID-19 Pandemic on the Gastrointestinal Cancer Stage at Diagnosis in Japa

Not Applicable
Conditions
Gastrointestinal Cancer
Registration Number
JPRN-UMIN000043873
Lead Sponsor
Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine
Brief Summary

The study evaluated 5167 patients. Comparing the preCOVID-19 period with the COVID-19 period, significant decreases were observed in the mean number of patients with newly diagnosed gastric cancer and colorectal cancer. Significant decreases were also observed in the mean number of cases of stage I gastric cancer, stage 0 colorectal cancer, and stage I colorectal cancer. A significant decrease was observed in the mean number of cases per month of stage II colorectal cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
5167
Inclusion Criteria

Not provided

Exclusion Criteria

Patients were considered eligible if they were diagnosed or started their first treatment (including palliative care) at the study hospitals and were considered ineligible if they were diagnosed and started their first treatment at other hospitals.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath